On June 4, 2018 Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, reported that two posters on Oraxol will be presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Meeting, taking place June 1-5, 2018 in Chicago, IL (Press release, Athenex, JUN 4, 2018, View Source;p=RssLanding&cat=news&id=2352942 [SID1234527121]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract Title: A phase I study to evaluate safety, tolerability, pharmacokinetics and activity of oraxol in patients (pts) with advanced malignancies.
Abstract ID: 2526
Dr Ma, Wan Wee (Mayo Clinic, Rochester, USA)
Poster Session: Clinical Pharmacology and Experimental Therapeutics
Date: 06/04/2018, 8:00 AM – 11:30 AM

Abstract Title: An open-label, randomized cross-over bioavailability and extension study of oral paclitaxel and HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumours.
Abstract ID: 2569
Dr Jackson, Christopher (Otago University, Dunedin, NZ)
Poster Session: Clinical Pharmacology and Experimental Therapeutics
Date: 06/04/2018, 8:00 AM – 11:30 AM